View in EDS

868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Saved in:
Bibliographic Details
Title: 868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Authors: Wong, W.1 (AUTHOR), Adkins, D.R.2 (AUTHOR), Misleh, J.G.3 (AUTHOR), Lorch, J.4 (AUTHOR), Grewal, J.S.5 (AUTHOR), Russell, J.6 (AUTHOR), Cetnar, J.7 (AUTHOR), Ho, A.L.1 (AUTHOR), Chen, K.8 (AUTHOR), Aysola, K.8 (AUTHOR), Thomas, J.9 (AUTHOR)
Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS622-S623. 2p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 179692325
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Wong%2C+W%2E%22">Wong, W.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Adkins%2C+D%2ER%2E%22">Adkins, D.R.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Misleh%2C+J%2EG%2E%22">Misleh, J.G.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lorch%2C+J%2E%22">Lorch, J.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Grewal%2C+J%2ES%2E%22">Grewal, J.S.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Russell%2C+J%2E%22">Russell, J.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cetnar%2C+J%2E%22">Cetnar, J.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ho%2C+A%2EL%2E%22">Ho, A.L.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+K%2E%22">Chen, K.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aysola%2C+K%2E%22">Aysola, K.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thomas%2C+J%2E%22">Thomas, J.</searchLink><relatesTo>9</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2024 Supplement 2, Vol. 35, pS622-S623. 2p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=179692325
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2024.08.929
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 2
        StartPage: S622
    Titles:
      – TitleFull: 868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wong, W.
      – PersonEntity:
          Name:
            NameFull: Adkins, D.R.
      – PersonEntity:
          Name:
            NameFull: Misleh, J.G.
      – PersonEntity:
          Name:
            NameFull: Lorch, J.
      – PersonEntity:
          Name:
            NameFull: Grewal, J.S.
      – PersonEntity:
          Name:
            NameFull: Russell, J.
      – PersonEntity:
          Name:
            NameFull: Cetnar, J.
      – PersonEntity:
          Name:
            NameFull: Ho, A.L.
      – PersonEntity:
          Name:
            NameFull: Chen, K.
      – PersonEntity:
          Name:
            NameFull: Aysola, K.
      – PersonEntity:
          Name:
            NameFull: Thomas, J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: 2024 Supplement 2
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 35
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1